Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacopa monnieri and Nardostachys jatamansi for Schizophrenia
NCT00483964Phase 2Completed
- Sponsor
- Q.Mundewadi Ayurvedic Research & Charitable Trust
- Start
- Sep 2005
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bacopa monnieri and nardostachys jatamansi in schizophrenia (2 arms), sponsored by Q.Mundewadi Ayurvedic Research & Charitable Trust. Primary endpoint: Positive and Negative Symptom Scale at 78 weeks. Started Sep 2005; status: completed.
02
Drugs
bacopa monnierinardostachys jatamansi
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00483964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483964.